June 21, 2022 A hematology fellow from Australia, Eddie Cliff, MPH 22, cares just as deeply about the well-being of his patients as he does about improving health systems as a whole. Hes also a writer published in the New York Times and on NPR, a Fulbright Scholar, and an advocate of healthy food and sustainability.
I grew up in Australia, where my grandmother was a nurse educator and my mom is a pediatric neurologist. Neither of them put any pressure on me to be interested in medicine, but I had some work experience with a neurologist, gastroenterologist, and a primary care physician and I found the combination of solving interesting problems and working with people appealed to me.
I fell in love with hematology by accident. I had planned to be an endocrinologist and work clinically on diabetes and obesity, with a parallel public health career focused on noncommunicable diseases and nutrition policy. Then I got rostered onto a hematology rotation, treating patients with myeloma and lymphoma with CAR T-Cell therapiesin which their own immune cells are genetically engineered to fight their cancerand I became fascinated by the science. With blood cancers and other blood disorders such as sickle cell disease, you are dealing with complex diseases, with interesting treatments, that affect people from all walks of life. Hematology also has a powerful human side; when I give a patient a scan result with good or bad news, I think carefully about how to break the news, and for each patient, we design a personalized treatment plan incorporating the values and priorities most important to them.
Working in Australia during the COVID-19 pandemic, I faced difficult conversations both on the COVID-19 wards and, subsequently, with blood cancer patients about end-of-life decisions while family members were barred from the hospital under COVID policy. I wrote about these dilemmas in an essay in JAMA Oncology titled A Decision Shared is a Decision Halved. Australias strategy for COVID was great, among the best in the world, and it saved tens of thousands of lives. Thats not to say there werent unintended consequences we perhaps didnt pay enough attention toincluding patients and families being unable to be togetherand those stories are also worth telling.
What got me into public health was hearing from leaders in the field like Atul Gawande and Michael Marmot, and getting involved with a nonprofit focused on preventing noncommunicable diseases called NCDFree, which I volunteered for during medical school at Monash University. If you look at society, the biggest killers are cardiovascular disease and stroke, and the biggest risk factor for those diseases, particularly in countries where smoking rates are low, is our food system. Big Food companies are manipulating our evolutionary drive for high-calorie, high-sugar, low-nutrition foods such as sugary drinks. I helped run a food festival called festival21 with many of the NCDFree team, led by Sandro Demaio, for 3,000 people that highlighted the intersection of food, health, and sustainability. I also got involved with the Australian Medical Students Association to advocate against things the government was doing to dismantle universal health coverage and deregulate university fees; to advocate for a soft-drink tax; and to contribute to campaigns on student mental health and blood donation.
The highlight of my time at Harvard was a course called Reimagining Global Health, taught by [the late Partners In Health cofounder] Paul Farmer, and three other leading medical anthropologists, Arthur Kleinman, Salmaan Keshavjee, and Anne Becker. What was so life-changing was the way they took concepts from anthropology and social theory and applied them to their firsthand experiences in Peru, Haiti, Rwanda, Russia, China, Fiji, and elsewhere. For low- or middle-income countries, multilateral organizations often prioritize the most cost-effective things; for example, they may say that these countries dont need cancer drugs because we need to cure them of HIV and TB first. But global health is not just about addressing perceived low-hanging fruit such as distributing mosquito nets to prevent malaria, its also about building hospitals, training doctors and nurses, and developing a health care delivery system. The course made me want figure out how we can influence global systems to ensure better access to therapies around the worldas PEPFAR [The U.S. Presidents Emergency Plan For AIDS Relief]and similar program have achieved with HIV medicinesinstead of just kind of throwing up our hands and saying this is too hard.
For my current research, I work with Harvard Medical Schools Aaron Kesselheim and his group called PORTAL (Program on Regulation, Therapeutics and Law), to help advocate for lower prices for drugs and make them more accessible. A lot of the lessons I learned about Big Food also apply to Big Pharma. Just to give an example of how pharma companies work the system to their advantage, one company has 88 patents on a drug called ibrutinib, used to treat chronic lymphocytic leukemia (CLL). The patents prevent generic competitors from entering the market so that they can keep profiting from it for as long as possible. Sometimes in medicine, the basic science about curing cancer is really emphasized and celebrated, but if weve got these drugs and people cant access them because theyre too expensive, well, then havent we failed at our jobs anyway?
I am now doing a fellowship at PORTAL looking at the intersection of blood cancer medicine and public policy, doing research on pricing and regulation for drugs and cellular therapies such as CAR T-cells. My dream job would be to be an academic hematologist who could use my clinical work to feed into research, policy, and advocacy work to make society and the health system work better for all.
Im very passionate about classical music, and I play the oboe and percussion in orchestras. They are very different types of instruments, but I love them both. The oboe is a key player in the middle of the orchestra, where you feel like you are in the thick of things, whereas with percussion you are more exposed and cant hide. It turns out that my Harvard Chan adviser, Michael Barnett, is also an oboist! Music is a very mindful activity, where you learn very early on how to block out the crying baby in the second row of the audience. When they tried to teach us mindfulness in medical school, I realized I already learned it from playing music.
Michael Blanding
photo: Alex Lebrowski
See original here:
Bringing heart and humanity to hematology | News | Harvard TH Chan School of Public Health - HSPH News
- Cell-Based Regenerative Medicine Market Size to Witness Rapid Growth at a CAGR of 15% by 2032 | insightSLICE - EIN News - May 9th, 2023
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert - Economic Times - January 21st, 2023
- Cell culture - Wikipedia - December 18th, 2022
- The Legacy of Henrietta Lacks - Hopkins Medicine - December 10th, 2022
- HOME | Stem cell & Cancer - October 4th, 2022
- CAR T Cell Therapy Offers a New Hope in the Treatment of Severe and Refractory Systemic Lupus Erythematosus - Rheumatology Network - October 4th, 2022
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 4th, 2022
- Outlook on the Automated Cell Counters Global Market to 2028 - Use of Cell Counters in Personalized Medicine Presents Opportunities -... - October 4th, 2022
- Jcr Pharmaceuticals Co., Ltd. and Sysmex Establish A Joint Venture in the Field of Regenerative Medicine and Cell Therapy - Marketscreener.com - October 4th, 2022
- Growth in Cell and Gene Therapy Market - BioPharm International - October 4th, 2022
- Breakthrough in production of cancer-treating drug - Stanford University News - October 4th, 2022
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 4th, 2022
- Mary Munson elected fellow of the American Society for Cell Biology - UMass Medical School - October 4th, 2022
- 5 FDA decisions to watch in the fourth quarter - BioPharma Dive - October 4th, 2022
- bit.bio Adds Two New Human Cell Products to Address the Translation Gap and Accelerate Research and Drug Discovery for Neurodegenerative Disease -... - October 4th, 2022
- Laser Focus World highlights UC research that uses light to restore cell function - University of Cincinnati - October 4th, 2022
- The Institute of Regenerative Medicine | Non-Surgical, Cell-Based ... - September 25th, 2022
- CAR T-Cell Therapy Shows Promise in Treating Lupus - Healthline - September 25th, 2022
- ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit - El Paso Inc. - September 25th, 2022
- Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit - GlobeNewswire - September 25th, 2022
- Alzheimer's disease risk linked to newly discovered protein mutation - Medical News Today - September 25th, 2022
- Biological Links Identified Between an Aggressive Breast Cancer Type and African Ancestry - Weill Cornell Medicine Newsroom - September 25th, 2022
- The Use of Nanorobotics in the Treatment Therapy of Cancer and Its Future Aspects: A Review - Cureus - September 25th, 2022
- UW Health, UW-Madison School of Medicine and Public Health: Innovative clinical trial targets recurrent BK infection in kidney transplant recipients -... - September 25th, 2022
- Shutting down backup genes leads to cancer remission in mice - University of Michigan News - September 25th, 2022
- Pembrolizumab in Combination with Lenvatinib as First-Line Treatment for Non Clear Cell Renal Cell Carcinoma (nccRCC), KEYNOTE-B61 - Laurence Albiges... - September 25th, 2022
- FDA's ODAC Votes That Benefits Do Not Outweigh Risks for Poziotinib in HER Exon 20 Ins+ NSCLC - Targeted Oncology - September 25th, 2022
- Courageous Lanarkshire teen who survived leukaemia thanks to a clinical trial pursues nursing dream - Daily Record - September 25th, 2022
- Discovery Reveals How the Immune System Tolerates Friendly Gut Bacteria - Weill Cornell Medicine Newsroom - September 8th, 2022
- Study: New Factors Are Associated With Increased PFS from BCMA-Targeted T-Cell Therapy - Pharmacy Times - September 8th, 2022
- Study Uncovers Possible Path for Improving T Cell Therapies - University of Arizona - September 8th, 2022
- Trodelvy Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study - Gilead Sciences - September 8th, 2022
- Manipulating Astrocytes in Tumor Environment Effective Against Glioblastoma - Inside Precision Medicine - September 8th, 2022
- Jane Fonda Diagnosed with Non-Hodgkin's Lymphoma: What to Know - Healthline - September 8th, 2022
- Dr Hatim Husain: Biomarker Testing Is a Treatment Cornerstone in NSCLC - AJMC.com Managed Markets Network - August 30th, 2022
- Porton Advanced and Kun Tuo Announce Strategic Partnership to Deepen Gene and Cell Therapy CDMO and Clinical Research Services - PR Newswire - August 30th, 2022
- The Role of Eosinophils as a Biomarker to Inform Treatment Decisions for Patients With COPD - Consultant360 - August 30th, 2022
- Scientists Discover Surprise Anticancer Properties of Common Lab Molecule | Newsroom - UNC Health and UNC School of Medicine - August 30th, 2022
- Overall survival is similar for patients receiving CT-based or minimal follow-up after surgical resection of non-small-cell lung cancer - 2 Minute... - August 30th, 2022
- NSF Grant to Aid OSU Researchers Developing Treatment for Canine Cancer - The Corvallis Advocate - August 30th, 2022
- Researchers Identify the Target of Immune Attacks on Liver Cells in Metabolic Disorders - Weill Cornell Medicine Newsroom - August 22nd, 2022
- Why Is CAR T-Cell Therapy One of the Most Phenomenal Advances in Science? - University of Colorado Anschutz Medical Campus - August 22nd, 2022
- Porton Advanced Solutions completes a Series B financing round to expand its end-to-end Gene and Cell Therapy CDMO Platforms - PR Newswire - August 22nd, 2022
- Cell Analysis Global Market Report 2022: Growing Focus on Personalized Medicine & Introduction of Advanced Technologies in Cell Analysis Presents... - August 22nd, 2022
- Stress can throw off circadian rhythms and lead to weight gain - Medical News Today - August 22nd, 2022
- Cell Stress and Mitochondrial Dysfunction Found in Early Alzheimers Disease Patients, Findings Published in Science Translational Medicine - BioSpace - August 22nd, 2022
- Restoring cell and organ function after the heart stops - National Institutes of Health (.gov) - August 22nd, 2022
- Rolling the Dice: Gamble Pays Off For Cancer Patient in CAR T-Cell Clinical Trial - University of Colorado Anschutz Medical Campus - August 22nd, 2022
- Boosting neuron formation restores memory in mice with Alzheimer's disease - EurekAlert - August 22nd, 2022
- UTSW study finds p53 gene plays second role in suppressing genes tied to cancer - UT Southwestern - August 22nd, 2022
- GlyNAC supplementation reverses mitochondrial dysfunction, oxidative stress and aging hallmarks to boost strength and promote health in aging humans -... - August 22nd, 2022
- Multiple shots of the BCG vaccine protect type 1 diabetics from COVID-19 - EurekAlert - August 22nd, 2022
- Cell Regeneration Medicine Market Analysis by Type, Application, Growth, Demand, Status, and Forecast from 2022 to 2032 - Digital Journal - August 5th, 2022
- Higher Hydroxyurea Exposure Tied to Better Blood Parameters in US... - Sickle Cell Anemia News - August 5th, 2022
- Kiwis with multiple sclerosis patients thriving from overseas stem-cell treatment urge Government to approve it here - Newshub - July 27th, 2022
- MHRA grants marketing authorisation to Global Blood Therapeutics for sickle cell disease drug - PMLiVE - July 27th, 2022
- CAR T-Cell Therapy Turns 10 and Finally Earns the Word 'Cure' - Medscape - July 27th, 2022
- Oncology Peer Review On-The-Go: The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced NonSmall Cell Lung Cancer Treated... - July 27th, 2022
- CRISPR therapeutics can damage the genome - EurekAlert - July 27th, 2022
- To cell surface and beyond: Tracing subcellular glycoprotein transport using modified cholera toxin - EurekAlert - July 27th, 2022
- From Donor to Patient: Advancing the Future of Cell Therapies - Genetic Engineering & Biotechnology News - July 27th, 2022
- Five-Year Review of Biomedical Research Imaging Center, Center Director | Newsroom - UNC Health and UNC School of Medicine - July 27th, 2022
- Using Particles That Are Smaller Than the Head of a Pin to Treat Cancer - Yale School of Medicine - July 11th, 2022
- Stem Cell Assays Market Report 2022-2027: Increasing Awareness About Therapeutic Potency of Stem Cells Driving Growth - ResearchAndMarkets.com -... - July 11th, 2022
- Sickle cell disease could be treated with common plant, study finds - The Telegraph - July 11th, 2022
- Unexpected link between most common cancer drivers may yield more effective drugs - University of Wisconsin-Madison - July 11th, 2022
- Scientists Discover Key to Hepatitis A Virus Replication, Show Drug Effectiveness | Newsroom - UNC Health and UNC School of Medicine - July 11th, 2022
- How Erectile Dysfunction Drugs Can Help Treat Cancer and Save Thousands of Lives - SciTechDaily - July 11th, 2022
- Pune: Dr Mohan Wani appointed as director of National Centre for Cell Science - The Indian Express - July 11th, 2022
- Kite's CAR T-cell Therapy Yescarta Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma - Gilead... - July 3rd, 2022
- Important Factors for Regulating the Body's Immune Response - Neuroscience News - July 3rd, 2022
- Stem Cell Therapy Market Is Expected To Reach USD 455.61 Billion By 2027 At A CAGR Of 16 percent By Forecast 2027 Says Maximize Market Research (MMR)... - July 3rd, 2022
- Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with... - July 3rd, 2022
- Growing scope of Genetic Medicine and Stem Cell Research - The Hindu - June 22nd, 2022
- When children with sickle cell grow up, they face a system not designed for them - 89.3 WFPL News Louisville - June 22nd, 2022
- Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including... - June 22nd, 2022
- Stem Cell Assays Market worth $4.5 billion by 2027 - Exclusive Report by MarketsandMarkets - PR Newswire - June 22nd, 2022
- Belzutifan Improves Survival in Patients With RCC and VHL - Targeted Oncology - June 22nd, 2022
- Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and... - June 13th, 2022
- ASCO 2022: Gilead's tough weekend, bispecific progress and 'gamma delta' cell therapy - BioPharma Dive - June 13th, 2022